Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2022

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

000-53078

42-1743430

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2 Burlington Woods Drive, Ste. 100

Burlington, MA

01803

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (781) 552-4452

Securities registered pursuant to section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.001 par value per share	BBLG	The Nasdaq Stock Market LLC

Warrants to Purchase Common stock, $0.001 par value per share	BBLGW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

Annual Meeting of Stockholders

An annual meeting (“Annual Meeting”) of the stockholders of Bone Biologics Corporation, a Delaware corporation (the “Company”), was held on August 23, 2022. The Company filed its definitive proxy statement in connection with the Annual Meeting with the Securities and Exchange Commission on July 6, 2022 (which can be viewed at: www.sec.gov). The Company’s stockholders considered the following proposals at the Annual Meeting:

●	Proposal I: A proposal to elect Don Hankey, Stephen La Neve, Bruce Stroever, Erick Lucera and Siddhesh Angle to the Company’s Board of Directors; and

●	Proposal II: A proposal to approve on an advisory basis the compensation of the Company’s named executive officers; and

●	Proposal III: A proposal to ratify the appointment of Weinberg & Company, P.A., as our independent registered public accountant for the fiscal year ending December 31, 2022.

Voting Results

Proposal I: The election of the directors was approved as follows:

	FOR	WITHHELD	BROKER NON-VOTES

Don Hankey	7,301,750	10,154	666,720

Stephen La Neve	7,301,650	10,254	666,720

Bruce Stroever	7,299,542	12,362	666,720

Erick Lucera	7,300,254	11,650	666,720

Siddhesh Angle	7,266,793	45,111	666,720

Proposal II: Approval of Executive Compensation was approved with 7,271,303 “FOR” votes, 29,002 “AGAINST” votes, 11,599 “ABSTAIN” votes and 666,720 broker non-votes.

Proposal III: Ratification of the appointment of Weinberg & Company, P.A., as independent registered public accountant for the fiscal year ending December 31, 2022 was approved with 7,965,696 “FOR” votes, 1,274 “AGAINST” votes and 11,654 “ABSTAIN” votes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.